Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1273 granules vs active control in children with influenza A
CTR20254478Phase 3Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlatrelvir in Influenza A infection, sponsored by Raynovent Biotech. Started Nov 2025; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on CTR20254478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254478.